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ABSTRACT 
SCOPE: The aim of this study was to develop and evaluate a parallel reaction monitoring mass spectrometry 
(PRM-MS) assay consisting of a panel of potential protein biomarkers in cerebrospinal fluid (CSF). 
EXPERIMENTAL DESIGN: Thirteen proteins were selected based on their association with neurodegenerative 
diseases and involvement in synaptic function, secretory vesicle function, or innate immune system. CSF 
samples were digested and two to three peptides per protein were quantified using stable isotope-labeled 
peptide standards. 
RESULTS: Coefficients of variation were generally below 15%. Clinical evaluation was performed on a cohort of 
10 patients with Alzheimer's disease (AD) and 15 healthy subjects. Investigated proteins of the granin family 
exhibited the largest difference between the patient groups. Secretogranin-2 (p<0.005) and neurosecretory 
protein VGF (p<0.001) concentrations were lowered in AD. For chromogranin A, two of three peptides had 
significantly lowered AD concentrations (p<0.01). The concentrations of the synaptic proteins neurexin-1 and 
neuronal pentraxin-1, as well as neurofascin were also significantly lowered in AD (p<0.05). The other 
investigated proteins, β2-microglobulin, cystatin C, amyloid precursor protein, lysozyme C, neurexin-2, 
neurexin-3, and neurocan core protein, were not significantly altered. 
CONCLUSION AND CLINICAL RELEVANCE: PRM-MS of protein panels is a valuable tool to evaluate biomarker 
candidates for neurodegenerative disorders.  
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INTRODUCTION 
Alzheimer’s disease (AD) is characterized by accumulation of aggregated hyperphosphorylated tau protein in 
neurofibrillary tangles and amyloid β (Aβ) peptides in plaques.1-4 Knowledge on AD pathogenesis has resulted in 
several disease-modifying drug candidates that are being evaluated in clinical trials.5 However, many trials have 
suffered from the low diagnostic accuracy of pure clinical assessment of patients, meaning that a high proportion 
of patients that do not have AD pathology have been enrolled.6 Thus, there is a great need for biomarkers, both 
to improve diagnostics and to monitor treatment effects.7 
The most validated cerebrospinal fluid (CSF) biomarkers for AD are Aβ42, total tau (T-tau) and tau phosphorylated 
at threonine 181 (P-tau), which consistently have shown a marked change in AD dementia and also in the early 
prodromal phase of the disease.8 Based on their high diagnostic performance, these core AD CSF biomarkers 
have been included in the diagnostic criteria for AD.9,10 Even though these CSF biomarkers discriminate AD cases 
well from healthy subjects,11 additional understanding of the disease mechanisms could be obtained by new 
biomarkers reflecting other aspects of pathophysiology. Moreover, it is frequently difficult with differential 
diagnosis between AD and other forms of dementia. Early loss of synaptic function is believed to play an 
important role in AD and recently the CSF levels of peptide products from both presynaptic12,13 and postsynaptic14 
proteins have been shown to be altered in AD. Moreover, inflammatory processes15 and oxidative stress16 may 
be involved in AD pathogenesis. To better understand the complicated biochemistry leading to AD it is important 
to investigate complementary potential biomarkers. These may also be useful to improve the current diagnosis 
efficiency, in differential diagnoses of AD and other neurodegenerative diseases, and to monitor therapeutic 
effects. 
While the immunoassay is presently the workhorse in biomarker analysis, in the search for novel biomarker 
candidates, mass spectrometry offers possibilities when no suitable antibodies exist.17 Even if there is still a 
limited number of clinical studies performed, targeted mass spectrometric analysis of protein compounds is 
presently a fast growing research field.18 An advantage is the possibility for multiplexing, allowing for analysis of 
a number of compounds in one analysis. However, complex samples, such as CSF, require instrumentation that 
can provide the necessary selectAivity. The Q Exactive is a high-resolution instrument capable of parallel reaction 
monitoring (PRM), a method related to selected reaction monitoring (SRM) but with the advantage of acquiring 
full fragment spectra instead of a choice of preselected fragments. This feature, together with the high mass 
resolution, considerably increases the possibility to avoid interfering signals that compromises the obtained 
data.19,20 For the method to be robust and capable of handling large sample numbers without interruption it is, 
however, necessary to operate with a liquid chromatography (LC) system using larger columns and higher flow 
rates than typically employed in discovery work. Sensitivity is a key parameter for analysis of clinically relevant 
samples where available sample amounts are low. When operating in PRM mode the sensitivity is still very high 
and low femtomole levels can be quantified.21,22 
Based on exploratory mass spectrometry studies, we selected novel biomarker candidates, which were 
associated with neurodegenerative diseases, involved in synaptic function, secretory vesicle function, and in the 
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innate immune system. Neurosecretory protein VGF, secretogranin-2, chromogranin A all three belong to the 
granin family: Granins are expressed in endocrine cells and peptidergic neurons, are present in large dense core 
vesicles, and have been associated with neurodegenerative diseases such as AD, multiple sclerosis, 
schizophrenia, and depression.23 Secretogranin-2 and chromogranin A have been shown to colocalize and 
exhibited significantly lower immunoreactivity in AD brains.24 Both proteins have been found in amyloid 
plaques25 and high CSF chromogranin A levels are associated with longitudinal Aβ42 reduction.26 CSF biomarker 
studies on chromogranin A have yielded different results depending on the precise type of AD that was studied.27-
29 Cystatin C is a cysteine protease inhibitor affecting, for example, cathepsin B30 and BACE1; in the latter case 
directly leading to lower Aβ40 levels and increased sAPPα levels as measured in human brain microvascular 
endothelial cells.31 Cystatin C has been shown to bind to Aβ and thus diminishing Aβ deposits in mouse brain.32 
CSF β2-microglobulin levels are increased as a result of immune system activation and are found to be elevated 
in, for example, purulent meningitis, viral meningitis/encephalitis, and neuroborreliosis.33 For soluble amyloid 
precursor protein (sAPP) there is a number of studies conducted for total sAPP as well as for sAPPα and -β with 
different results concerning changes in level for AD compared to control patients.34-42 CSF lysozyme C levels are 
increased in bacterial and fungal meningitis and acute inflammatory conditions.43 Lysozyme C is shown to co-
localize with Aβ, to prevent Aβ aggregation in vitro as well as in Drosophila melanogaster, and to be increased in 
AD CSF.44 Neurexin-1, -2, and -3 are transmembrane proteins found in presynaptic terminals. Neurexins act as 
neuronal cell-surface receptors but the precise function and localization of the different variants is yet to be 
elucidated.45 Recently, Schreiner et al.46 performed a thorough investigation of neurexin profiling and relative 
distribution in the brain and concluded that neurexins are relatively abundant synaptic proteins and that the 
alpha isoforms were more abundant than the beta isoforms. Neuronal pentraxin-1 is a member of the pentraxin 
family, which members are involved in neurodegeneration,47 and is found in pre- and post-synaptic 
compartments of excitatory synapses.48 Neuronal pentraxin-1 colocalizes with both SNAP-25 and tau in 
dystrophic neurites surrounding amyloid deposits in human brain.49 Neurofascin occurs in several isoforms, 
which are expressed in immature neurons and involved in neurite outgrowth and control of postsynaptic 
structures; expressed in mature neurons and involved in synaptic stabilization; and expressed in glia and involved 
in in stabilization of paranodes.50,51 Neurocan core protein has been shown to be expressed by reactive astrocytes 
in mice subjected to cortical brain injury and by astrocytes in primary cell culture.52 Neurocan core protein has 
also been shown to increase in astrocytes incubated with Aβ, possibly via Sox9 regulation.53 
For the thirteen selected proteins we aimed to develop two biomarker panels for a sufficient sensitive work-
load-efficient method robust enough for large sample sets. This was accomplished by adding of internal 
standards to the CSF, tryptic digestion in solution followed by SPE desalting and concentration step with 
subsequent drying of the samples. Reconstituted samples were then analysed by LC-PRM-MS. These biomarker 
panels were evaluated in CSF samples from a cohort of AD patients and controls. 
 
MATERIALS AND METHODS 
General 
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Quantitative mass spectrometric analysis of intact proteins is presently not feasible. By digestion, a number of 
peptides suitable for MS analysis are obtained. From previous nanoflow LC-MS analyses two or three suitable 
peptides were selected for each protein chosen to investigate. For PRM analysis, corresponding stable-isotope-
labeled peptides are used as reference peptides in the LC-MS analyses. In addition, human albumin, which is not 
produced in the central nervous system, was monitored and bovine serum albumin (BSA) protein was added 
together with one corresponding stable isotope-labeled peptide. BSA, having the same level in all samples, was 
used to monitor the general performance, e.g., digestion efficiency. To ensure good quality data the mass 
spectrometer was operated in a relatively slow mode with long injection times per acquisition. This put limits on 
the maximum number of peptides that could be handled simultaneously and therefore the analysis was divided 
into two panels, each analysing 17 or 18 peptides. The time between injections was 72 min, of which 7 min was 
sample loading time. To monitor intra- and inter-day variations a CSF pool was aliquoted and used for quality 
control. A schematic of the workflow is shown in Fig. 1. 
 
CSF samples 
Samples from ten patients (6 males, 4 females) diagnosed with AD and fifteen healthy controls (9 males, 6 
females) from the Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark, were analysed. 
Age for the AD group was 64.9 ± 7.6 years (mean ± standard deviation) and 62.7 ± 7.0 years for the control 
group. The project was approved by the ethical committee of the Copenhagen Capital Region and all patients 
gave informed consent. 
CSF samples (10-12 mL) were obtained by lumbar puncture, collected in polypropylene tubes and gently mixed. 
The samples were centrifuged at 2000×g for 10 min at +4 °C to remove cells and other insoluble material and 
stored in polypropylene tubes at –80 °C pending analysis. 
Samples were thawed, and divided into 100-µL-aliquots in Micronic 0.75 mL tubes with screw caps (Micronic, 
Lelystad; The Netherlands), refrozen and stored at –80 °C pending further preparation. The CSF pool was a 
mixture of CSF obtained from the Neurochemistry Laboratory at Sahlgrenska University Hospital, Mölndal, 
Sweden. It was divided and stored in the same way as the individual CSF samples. 
 
Patients and AD biomarker analysis 
Patients were divided into AD and control groups based on clinical evaluation as well as on the result of a 
computer tomography (CT) scan. The samples included in the control group all came from volunteers that were 
deemed not having any mental disorder. For the AD group an additional criterion for inclusion was a low CSF 
Aβ42 level, to assure patients having brain amyloid deposition. The CSF Aβ42 levels were determined at Statens 
Serum Institute, Copenhagen, Denmark, using Fujirebio immunoassay, and were 275.4 ± 106.8 pg/mL (mean ± 
standard deviation) for the AD group and 877.2 ± 206.3 pg/mL for the control group; P-value <10–4 (Student’s t-
test). 
 
Standards 
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Peptides to be analysed were identified previously by analysing trypsin digested CSF using nanoflow LC-MS/MS. 
Peptides providing a good enough signal and identification score were further investigated and verified to 
represent only the proteins of interest. Heavy-isotope-labeled standards were purchased from Thermo Fisher 
Scientific Inc. (Waltham, MA, USA; FasTrack 1, usable for relative measurements). BSA protein was from Sigma-
Aldrich Co. (Saint Louis, MO, USA). Peptides and BSA protein were dissolved in water or water/acetonitrile/formic 
acid 100/30/1 (v/v/v) and diluted individually in 50 mM NH4HCO3 to match protein levels in CSF samples. Diluted 
labeled peptides and BSA protein was pooled, aliquoted, and stored in solution at –20 °C pending further 
preparation. A parallel set of more concentrated standards (also diluted in 50 mM NH4HCO3) was prepared from 
the same stock solutions of heavy-isotope-labeled standards and BSA protein. These were then used to generate 
reverse calibration curves to evaluate the linearity and limits of quantification for each peptide in the assay. 
 
Reverse calibration samples 
Calibration samples were prepared by starting with the more concentrated standard solution and perform a two-
step dilution in 50mM NH4HCO3 producing a 10 000-fold concentration range of standards. These standard mixes 
were then added to CSF pool samples to generate reverse calibration curves, which were used to determine 
linearity and limits of quantification. The quantification limit was defined so that the CV at a particular point 
should be less than 25%. 
 
CSF protein digestion 
Frozen 100-µL CSF samples (individual and pool) were thawed and 20 µL of the thawed standard cocktail was 
added to each sample. For calibration samples the respective calibration standard cocktails were added to CSF 
pool samples. Reduction of sulphur bridges was performed by adding 25 µL of 30 mM 1,4-dithiothreitol (DTT, 5 
mM end conc., Sigma-Aldrich) in 50 mM NH4HCO3. Samples were then incubated at +60 °C for 30 min on gentle 
shaking using a Thermomixer Comfort (Eppendorf). After a cooling period of 30 min and subsequent spin-down, 
blocking of sulphur bridges was performed by adding 25 µL of 14 mM iodoacetamide (IAA, 2 mM end conc., 
Sigma-Aldrich) in 50 mM NH4HCO3 with subsequent incubation for 30 min at room temperature in darkness on 
gentle shaking. Digestion was performed by adding 25 µL of 0.8 µg/µL sequencing grade modified trypsin 
(Promega) in 50 mM NH4HCO3 and incubate over night (approximately 18 h) at +37 °C on gentle shaking. After a 
spin-down incubation was ended by adding 25 µL of 10% trifluoroacetic acid. 
 
Desalting and reconstitution 
Digested samples were desalted using Oasis 30 µm HLB 96-well µElution Plates (Waters). Wells were conditioned 
using 2×300 µL MeOH and equilibrated with 2×300 µL water using a rotary pump for controlled suction. Samples 
were the loaded onto the plate and the wells washed with 2×300 µL water. Samples were eluted with 2×100 µL 
MeOH into Micronic 0.75-mL tubes, which were dried in a speedvac and stored at –80 °C pending PRM analysis. 
Prior to PRM analysis samples were reconstituted in 50 mM NH4HCO3 and split as desired for each analysis set. 
The equivalent of 25 µL CSF was used for panel 1 and 50 µL for panel 2 (see Table 1). The two analyses were 
performed at two occasions, separated by two days. 
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LC-MS/MS analysis 
Mass spectrometric analysis was performed using a Dionex 3000 system (SRD-3600 degasser, WPS-3000TRS 
autosampler, HPG-3400RS pump, Thermo Fisher Scientific) coupled to a Q Exactive (Thermo Fisher Scientific) 
electrospray ionization hybrid quadrupole–orbitrap high resolution mass spectrometer. Separation was 
performed with a Hypersil Gold reversed phase column (id 2.1 mm, length 100 mm, Thermo Fisher Scientific) 
operated at a flowrate of 100 µL/min. For each assay the gradient was tailored to maximize separation of the 
peptides to be analysed. For both panels the mobile phase A was 0.1% formic acid, mobile phase B was 84% 
ACN/0.1% formic acid (v/v), the gradient was 50 min., and the sample cycle time was 75 min. MS analysis was 
performed as scheduled PRM with retention time windows no shorter than 4 min for each peptide. At most four 
different peptide pairs were toggled between, see Fig. S1. For general acquisition, including the study, isolation 
window was set to 8 m/z units enabling simultaneous acquisition of both “native” and labeled peptides. For 
comparison, in a limited number of analyses, isolation window was instead set to 3 m/z units with separate 
acquisitions of unlabeled and labeled peptides. The automatic gain control target value was set to 3x106 and 
maximum injection time to 300 ms for both precursor and fragment ion spectra. Acquisitions were made at a 
resolution setting of 70 000 (to match the maximum injection time) toggling between intact peptide and 
fragment mass spectra. 
 
Data processing 
Data processing was performed with PinPoint v1.3 (Thermo Fisher Scientific), which was used to generate peak 
areas of the “native” and labeled peptides. Extracted ion chromatograms for all transitions were inspected 
visually and those with peak shape differing from the internal standard were removed from the data set. Data 
was subsequently exported and further analysed using in-house developed software (PinPointEvaluator), which 
facilitated quality control and further refinement. Again, non-conformative transitions (e.g., transistions with 
light-to-heavy ratio different than the majority’s), likely affected by interferences, as well as those with low 
intensity, were removed. The CSF pool samples were utilized to evaluate the stability of the method. 
 
Statistical analysis 
Statistical analysis and plot generation was performed using GraphPad Prism 7.02. For the evaluation two-tailed 
Mann Whitney U test was used and P-values <0.05 were considered significant. Because the experimental 
approach was of a screening type rather than testing a full model hypothesis no further correction of significance 
values was required. 
 
RESULTS 
Evaluation of the PRM acquisition procedure 
The standard approach to set up parameters for SRM or PRM is to acquire unlabeled “native” and labeled 
compounds in separate acquisitions. To obtain good signals for the majority of the peptides analysed relatively 
long C-trap injection times (300 ms) were required. This meant that the number of data point acquired over the 
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chromatographic peak was on the low side. Because the limiting factor was the sensitivity therefore requiring 
long filling times, the instrument’s trapping multiplexing possibility would give no advantage (this operating 
mode is useful when the ion signal is relatively high, but a higher resolution is required for peak separation). 
Since the m/z difference between the compounds used was relatively low (5 m/z units or less) we investigated 
the simultaneous isolation of both unlabeled “native” and labeled using an 8 m/z unit isolation window. Since 
the instrument should have a dynamic range of >104 this should be no problem provided that the abundance 
difference between unlabeled “native” and labeled was well within this range. Apart from obtaining twice the 
number of data points, effects from variation in the electrospray current would be minimized. Refinement of the 
acquired data was required to remove transitions affected by interferences, see Table S1 for a list of the 
transitions used for quantification and Fig. S2 for extracted ion chromatograms of transitions used for 
quantification as well as tandem mass spectrum examples. 
The two approaches were evaluated using pool CSF and were found to give very similar results (Fig. 2a). The 
coefficient of variation (CV) was more or less the same. The average CV for the standard approach with separate 
isolation/acquisitions was 5.4% while it was 4.9% with simultaneous isolation. One difference was noted, 
however; the unlabeled “native”-to-labeled peptide ratio was different for the two approaches and was between 
1.2 and 1.8 times higher (peptide dependent) when using separate acquisitions (Fig. 2a). 
Acquisitions in SIM mode were also evaluated to evaluate the possibility to attain better sensitivity and utilizing 
the high resolution (together with MS/MS data for identification) to retain selectivity. However, it turned out 
that due to interferences it was for many of the peptides not possible to to obtain useful quantitative data. 
 
Reverse calibration and quality control samples 
The evaluation of the assay was performed by using pooled CSF. Reverse calibration curves spanning 4 orders of 
magnitudes were generated by spiking different amounts of the isotope labeled standards and BSA protein to 
100 µL of CSF. Depending on peptide, the 1-3 lowest concentration points did not produce quantifiable signals; 
see Table S2 and Fig. S3 for details. Pool CSF samples were prepared and analysed as QC samples at two separate 
occasions, see Table S3 and Fig. 2b, c. One of these occasions was at the time of patient sample analysis to 
monitor the robustness and the digestion efficiency also for the study sample set preparation. In all samples the 
added BSA labeled peptide and unlabeled protein was also used to monitor the stability and digestion quality. 
Generally the CVs for the peptide concentrations obtained for the two panels were below 15%. During the 
acquisitions every eight sample was a blank to monitor carry-over, which was negligible during the whole 
acquisition period (≤0.1%). 
 
Study samples 
The assay was evaluated using a cohort of samples from the Danish Dementia Research Centre. All samples were 
prepared at the same day but each PRM panel was analysed at different occasions separated by four days. The 
results from the first panel are presented in Fig. 3. Of the proteins analysed it is clear that for β2-microglubulin 
and APP there is no significant difference between the groups. The best separation between the AD and control 
groups was obtained for neurosecretory protein VGF (P<0.001) and for secretogranin-2 (P<0.005) which were 
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both lowered in AD. For cystatin C and chromogranin A the situation is less clear since one peptide for each 
protein is not significantly altered while the others are lowered. In Fig. 4 the results from the second panel are 
presented. Lysozyme C, neurexin-2, and neurocan core protein exhibit no significant difference between the 
patient groups. The peptides representing neurexin-1, neuronal pentraxin-1, and neurofascin were all 
significantly lowered (P<0.05) while only one peptide showed decreased level for neurexin-3. Notable also is that 
for all peptides exhibiting difference the levels are lower in AD. The control peptides from human albumin and 
BSA were analysed in both panels and produced very similar results at the two analysis time points. (Fig. S4). As 
can be seen in panels c and f, the sample-to-sample variation for BSA was low. 
 
DISCUSSION 
Evaluation of the PRM acquisition procedure 
The use of a high-resolution mass spectrometer capable of PRM provides both the advantage not to have to 
select the transitions in advance as well has having a very high degree of selectivity. Using high resolution MS we 
were able to investigate and evaluate possible interferences. We examined the possibility to use SIM acquisitions 
to monitor peptide precursor ion signals for the assay but that proved to be impossible because the limited 
specificity in this complex type of sample. However, we could use the SIM scans for trouble shooting. In the 
future there should be no need to collect SIM scans. With the additional selectivity step of monitoring product 
ions these interferences affected the quantification to a substantially lower degree and could be handled 
succesfully. Collection of signals from all product ions in a full MS/MS acquisition enabled us to refine the data 
by examining the unlabeled “native”-to-labeled transition intensity ratios. We could afford to remove transitions 
which ratios were different than that of the majority. Since LC conditions vary between analysis occasions a 
transition that was good at one occasion might not be useful due to an interfering signal at another. 
Since there was no apparent disadvantage with the simultaneous isolation approach we decided to conduct the 
study accordingly. The main advantage, as stated above, was the doubled acquisition speed allowing for a more 
efficient analysis. Some caution is however required, which is reflected in the difference in unlabeled “native”-
to-labeled peptide ratio which had a relative discrepancy of a factor about 1.6 between the acquisition 
approaches. The reason for this is that the isolation potential in the quadrupole is not entirely symmetric and 
may be further skewed with accumulation of deposits on the quadrupole 54. This causes a non-symmetric but 
reproducible isotope mass distribution (the distribution will slowly shift with deposit increase over a period of 
weeks or months depending on usage; quadrupole cleaning is required at regular intervals to keep the sensitivity 
up). The shift was experimentally supported by the positive correlation of the effect with peptide m/z difference, 
where the ratio differed least for the peptides pairs with heavy isotope labeled lysine (Δm = 8 Da; Δm/z = 4) and 
most for those with heavy isotope labeled arginine (Δm = 10 Da; Δm/z = 5), see Fig. 2a. With an isolation window 
of 8 m/z units peptide pairs with larger m/z difference will be closer to the edge of the non-symmetric isolation 
potential well and thus more affected. Note that this would not affect the measured peptide levels since an 
accurate abundance level has to be determined using an abundance characterized unlabeled peptide anyway. 
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The approach has been successfully implemented previously both by our laboratory55 and others.56 When 
attempting this approach with an abundance difference of 103 or higher the low intensity peak reproducibility 
was reduced (data not shown) and the standard approach with separate isolations should be used. Gallien, et al. 
has investigated different acquisition approaches and suggest that a broader isolation window, e.g., 8 m/z units, 
would lead to increased background and also reduced signal intensity57 but this was no problem with our current 
assays. There was a fair amount of co-isolation but not to the extent that the filling time was reduced. Care 
should, however, be taken if trap filling times get shorter than anticipated. This could mean that other compound 
eluting at the same time and having similar m/z to the compound of interest. If possible then a more narrow 
isolation window should be used. 
 
Reverse calibration and quality control samples 
From the standard curves it can be seen that the levels of the measured peptides were within the linear range; 
see Table S2 for quantification ranges. The overall reproducibility was deemed sufficient; CVs of about 15% is 
normal for these types of measurements. The column carry-over was carefully examined. It was 0.1% or lower 
depending on peptide, where carry-over correlated with hydrophobicity. By injecting a blank after every eight 
samples we could monitor the carry-over and verify that there was no visible build-up with consecutive 
injections. 
 
Study samples 
The first panel contained a number of proteins that have previously been implicated in AD and other neurological 
disorders. β2-microglobulin has been previously shown to have both increased CSF levels in AD58,59 and 
decreased or non-altered levels in mild dementia depending on analysis method.29 In the present study β2-
microglobulin was clearly not significantly altered in AD. Although CSF levels for soluble α and β variants of sAPP 
have been assayed relatively thoroughly with variable results,34-42 fewer studies have been conducted for the 
three splice variants of APP (APP695, APP751, and APP770). Splice variants containing the Kunitz protease 
inhibitory (KPI) encoded region (i.e., APP751 and APP770) have been shown to be increased relative to the non-
KPI containing APP695 in AD brains compared to control brains, see for example.60-62 In the present study, 
however, neither the peptide representing total APP nor the peptide representing APP containing the KPI domain 
were significantly altered in AD. CSF cystatin C levels have previously been reported to be decreased in AD,29,63 a 
result that is partially confirmed in the present study where both peptides appeared to be lowered in AD, but 
only one at a significant level.  
The most significantly altered proteins, secretogranin-2 and neurosecretory protein VGF, both belong to the 
granin family and both had lowered CSF levels in AD. For the third granin family member investigated, 
chromogranin A two peptides of three were also significantly down-regulated. These results are in line with 
previous reports. Endogenous secretogranin-2 peptides have previously been shown to have decreased CSF 
levels in AD64 which is the case also for endogenous VGF peptides.59,64-66 Endogenous chromogranin A peptide 
levels in CSF have been reported decreased in AD64,65 The third chromogranin A peptide, CHGA_194-213, did not 
correlate well with the other two and exhibited no significant difference between the AD and control groups. 
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The reason for this remains elusive and would need further investigations to explain. Proteins in CSF, including 
chromogranin A, are to a large extent present in various processed forms.67  
The proteins in panel 2 are much less investigated. In the present study CSF lysozyme level was not significantly 
altered in AD, a result contradicting the one previously published study on lysozyme C by Helmfors et al.44 where 
increased CSF levels were reported for AD. Neurexin-1 has previously been reported to be lowered in AD CSF,64 
and our results corroborate this finding. For the remaining proteins in panel 2 this is to our knowledge the first 
investigation on AD CSF levels that has been reported. Two of the other proteins in panel 2, neuronal pentraxin-
1 and neurofascin, also exhibited lowered AD CSF levels (also just below the 0.05 significance level). Analysis of 
a larger cohort preferably including other disease types would be required to evaluate the usefulness of these 
proteins as biomarkers for AD or other neurodegenerative diseases. 
 
CONCLUSIONS 
The two-panel assay is sufficiently robust with CVs generally below 15% and can be applied to larger study sets. 
The addition of BSA protein and labeled peptide proved to be very useful for keeping track of tryptic digestion 
efficiency and general method robustness monitoring. Using a slightly wider isolation window of 8 m/z units 
proved to be advantageous with a doubling of measured data points and limiting spray variability effects. 
Thirteen proteins were investigated in the pilot study; of these, secretogranin-2, neurosecretory protein VGF, 
and two out of three chromogranin A peptide had markedly lowered levels in the AD patient group, confirming 
earlier studies; the reason for the third chromogranin A peptide’s discrepancy is presently not clear. A similar 
result was obtained for cystatin C where one peptide was significantly lowered in AD and the other not. Neurexin-
1, neuronal pentraxin-1, and neurofascin were also lowered in AD; at a confidence level of 0.05. The remaining 
proteins exhibited a moderate significant difference for only one out of two peptides or for none of them. These 
findings for AD have to be validated with further studies and it would be very interesting to apply the method to 
other neurodegenerative diseases to investigate the potential for differential diagnosis. 
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Tables: 
 
Table 1. Internal standard peptide characteristics. 
Protein 
Protein 
mass 
[kDa] 
Peptide sequencea 
Amino acid 
positions 
Estimated 
conc. for 
ratio=1 
[nmol/L] 
Cystatin Cb 13.3 
LVGGPMDASVEEEGV[R] 35-50 140 
ALDFAVGEYN[K] 52-62 360 
β2-microglobulinb 11.7 
VEHSDLSFS[K] 69-78 84 
VNHVTLSQP[K] 102-111 90 
Neurosecretory protein 
VGFb 
65.0 
NSEPQDEGELFQGVDP[R] 64-80 120 
AYQGVAAPFP[K] 268-278 1.9 
Chromogranin Ab 48.9 
YPGPQAEGDSEGLSQGLVD[R] 194-213 33 
GLSAEPGWQA[K] 216-226 2.8 
EDSLEAGLPLQV[R] 400-412 2.9 
Secretogranin-2b 67.8 
ALEYIENL[R] 58-66 1.1 
VLEYLNQE[K] 593-601 2.4 
APP (751/770 isoform) b 83.0 EV(C)SEQAETGP(C)[R] 289-301 5.0 
APPb 85.2 VESLEQEAANE[R] 439-450 5.0 
Lysozyme Cc 14.7 
WESGYNT[R] 52-59 9.8 
STDYGIFQINS[R] 69-80 4.4 
Neurexin-1c 158.8 
LTVDDQQAMTGQMAGDHT[R] 823-841 26 
VDSSSGLGDYLELHIHQG[K] 1168-1186 9.7 
Neurexin-2c 182.0 
TALAVDGEA[R] 124-133 4.3 
VDLPLPPEVWTAAL[R] 637-651 3.9 
Neurexin-3c 177.8 
FI(C)D(C)TGTGYWG[R] 665-677 4.9 
LTVDDDVAEGTMVGDHT[R] 790-807 1.2 
Neuronal pentraxin-1c 45.0 
LENLEQYS[R] 144-152 9.6 
LTPGEVYNLAT(C)ST[K] 386-400 7.7 
Neurofascinc 147.5 
GNPAPSFHWT[R] 67-77 9.8 
VIAINEVGSSHPSLPSE[R] 702-719 2.5 
Neurocan CPc 140.7 
ELGGEVFYVGPA[R] 257-269 1.6 
DFQWTDNTGLQFENW[R] 1155-1170 13 
Albuminb, c 66.4 
L(C)TVATL[R] 098-105 850 
AEFAEVS[K] 250-257 900 
Bovine albuminb, c 66.4 LGEYGFQNALIV[R] 421-433 130 
 
a [X] indicates stable isotope labeled amino acid and (C) indicates carbamidomethylated cysteine; b Included in panel 1; c 
Included in panel 2.  
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Figures: 
 
Figure 1. Schematic of the methodological workflow. 
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Figure 2. Mean ratios for QC pool CSF samples when using separate acquisitions for the unlabeled “native” 
peptide and the internal standard peptide (blue, n = 8) and acquisitions where both peptides are acquired 
simultaneously (red, n = 8) (a). Mean ratios for QC pool CSF samples at two different preparation and acquisition 
occasions for peptides included in (b) panel 1 (n = 13 + 14) and (c) panel 2 (n = 13 + 14). L/H ratio denotes light-
to-heavy peptide ratio. Error bars indicate standard deviation. 
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Figure 3. CSF level difference in control (C) vs AD groups for the peptides included in panel 1. For β2-microglubulin 
(a, b) and APP (l, m) none of the peptides exhibited a significant difference. For cystatin C (c, d) one out of two 
peptides was significantly lowered in AD and for chromgranin A (e, f, g) two out of three peptides were 
significantly lowered in AD. The most confident differences were obtained for secretogranin-2 (h, i) and 
neurosecretory protein VGF (j, k) for which both peptides were significantly lowered in AD. Control n = 15 and 
AD n = 10. L/H ratio denotes light-to-heavy peptide ratio.  
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Figure 4. CSF level difference in control (C) vs AD groups for the peptides included in panel 2. For lysozyme C (a, 
b), neurexin-2 (e, f), and neurocan core protein (m, n) none of the peptides exhibited a significant difference. For 
neurexin-3 (g, h) one out of two peptides was significantly lowered in AD. For neurexin-1 (c, d), neuronal 
pentraxin-1 (i, j), and neurofascin (k, l) both peptides were significantly (P<0.05) lowered in AD. Control n = 15 
and AD n = 9. L/H ratio denotes light-to-heavy peptide ratio. 
17 
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Supporting Information: 
 
Table S1. PRM transition characteristics. 
Protein Peptide sequencea 
Amino acid 
positions 
Precursor 
ion charge 
Product ions used for 
quantification 
Cystatin Cb 
LVGGPMDASVEEEGVR 35-50 2+ 
y6+, y7+, y8+, y9+, y10+, 
y11+, y12+, y14+ 
ALDFAVGEYNK 52-62 2+ y5+, y6+, y7+, y8+, y9+ 
β2-microglobulinb 
VEHSDLSFSK 69-78 3+ y3+, y4+, y5+, y7+ 
VNHVTLSQPK 102-111 3+ y4+, y5+, y6+, y7+ 
Chromogranin Ab 
YPGPQAEGDSEGLSQGLVDR 194-213 3+ 
y3+, y4+, y5+, y6+, y7+, y8+, 
y9+ 
GLSAEPGWQAK 216-226 2+ y6+, y7+, y8+, y9+ 
EDSLEAGLPLQVR 400-412 2+ 
y3+, y5+, y6+, y7+, y8+, y9+, 
y10+ 
Secretogranin-2b 
ALEYIENLR 58-66 2+ y4+, y5+, y6+, y7+ 
VLEYLNQEK 593-601 2+ y4+, y5+, y6+, y7+ 
Neurosecretory 
protein VGFb 
NSEPQDEGELFQGVDPR 64-80 2+ 
y3+, y5+, y6+, y7+, y8+, 
y10+, y11+, y12+ 
AYQGVAAPFPK 268-278 2+ y4+, y5+, y6+, y7+, y8+, y9+ 
APP (751/770 
isoform) b 
EV(C)SEQAETGP(C)R 289-301 2+ y4+, y5+, y6+, y7+, y8+ 
APPb VESLEQEAANER 439-450 2+ 
y3+, y4+, y5+, y6+, y7+, y8+, 
y10+ 
Lysozyme Cc 
WESGYNTR 52-59 2+ y3+, y4+, y5+, y7+ 
STDYGIFQINSR 69-80 2+ 
y3+, y4+, y5+, y6+, y7+, y8+, 
y9+, y10+ 
Neurexin-1c 
LTVDDQQAMTGQMAGDHTR 823-841 3+ 
y3+, y5+, y6+, y7+, y9+, 
y10+, y11+, y12+ 
VDSSSGLGDYLELHIHQGK 1168-1186 4+ y3+, y4+, y5+, y6+, y7+, y8+ 
Neurexin-2c 
TALAVDGEAR 124-133 2+ y5+, y6+, y7+, y8+ 
VDLPLPPEVWTAALR 637-651 2+ y9+, y10+, y11+ 
Neurexin-3c 
FI(C)D(C)TGTGYWGR 665-677 2+ 
y5+, y6+, y7+, y8+, y9+, 
y10+, y11+ 
LTVDDDVAEGTMVGDHTR 790-807 3+ y5+, y6+, y9+, y10+, y11+ 
Neuronal 
pentraxin-1c 
LENLEQYSR 144-152 2+ y3+, y6+, y7+, y8+ 
LTPGEVYNLAT(C)STK 386-400 2+ 
y3+, y4+, y5+, y6+, y7+, y8+, 
y9+, y10+, y12+, y13+ 
Neurofascinc 
GNPAPSFHWTR 67-77 3+ y4+, y5+, y6+ 
VIAINEVGSSHPSLPSER 702-719 3+ 
y5+, y6+, y7+, y8+, y10+, 
y11+, y12+ 
Neurocan CPc 
ELGGEVFYVGPAR 257-269 2+ 
y3+, y4+, y5+, y6+, y7+, y8+, 
y9+, y10+ 
DFQWTDNTGLQFENWR 1155-1170 3+ y3+,y4+, y5+, y6+, y8+ 
Albuminb, c 
L(C)TVATLR 098-105 2+ y3+, y4+, y5+, y6+, y7+ 
AEFAEVSKd 250-257 2+ y3+, y4+, y5+, y6+, y7+ 
Bovine albuminb, c LGEYGFQNALIVR 421-433 2+ 
y3+, y4+, y5+, y6+, y7+, y8+, 
y9+, y10+, y11+, y12+ 
 
a (C) indicates carbamidomethylated cysteine; b Included in panel 1; c Included in panel 2, d y3+ included only in panel 2.  
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Table S2. Reverse calibration dilution data. Estimated internal standard peptide concentrations for highest and 
lowest quantifiable points. Limits were set so that a CV below 25% was required for acceptance. 
Protein 
Amino acid 
positions 
Sequencea 
Highest 
[nmol/L] 
Lowest 
[nmol/L] 
Cystatin C 
35-50 LVGGPMDASVEEEGV[R] 1400 0.47 
52-62 ALDFAVGEYN[K] 1800 6.0 
β2-microglobulin 
69-78 VEHSDLSFS[K] 2500 25 
102-111 VNHVTLSQP[K] 900 3.0 
Chromogranin A 
194-213 YPGPQAEGDSEGLSQGLVD[R] 990 9.9 
216-226 GLSAEPGWQA[K] 83 0.28 
400-412 EDSLEAGLPLQV[R] 88 0.29 
Secretogranin-2 
58-66 ALEYIENL[R] 33 0.11 
593-601 VLEYLNQE[K] 71 0.24 
Neurosecretory 
protein VGF 
64-80 NSEPQDEGELFQGVDP[R] 590 5.9 
268-278 AYQGVAAPFP[K] 58 0.19 
APP 751/770 289-301 EV(C)SEQAETGP(C)[R] 25 0.25 
APP 439-450 VESLEQEAANE[R] 25 0.25 
Lysozyme C 
52-59 WESGYNT[R] 290 0.97 
69-80 STDYGIFQINS[R] 130 0.43 
Neurexin-1 
823-841 LTVDDQQAMTGQMAGDHT[R] 780 2.6 
1168-1186 VDSSSGLGDYLELHIHQG[K] 290 0.97 
Neurexin-2 
124-133 TALAVDGEA[R] 130 0.43 
637-651 VDLPLPPEVWTAAL[R] 120 0.40 
Neurexin-3 
665-677 FI(C)D(C)TGTGYWG[R] 150 0.50 
790-807 LTVDDDVAEGTMVGDHT[R] 35 0.35 
Neuronal 
pentraxin-1 
144-152 LENLEQYS[R] 290 0.97 
386-400 LTPGEVYNLAT(C)ST[K] 230 0.77 
Neurofascin 
67-77 GNPAPSFHWT[R] 290 0.97 
702-719 VIAINEVGSSHPSLPSE[R] 74 0.25 
Neurocan CP 
257-269 ELGGEVFYVGPA[R] 49 0.16 
1155-1170 DFQWTDNTGLQFENW[R] 390 1.3 
Albumin 
098-105 L(C)TVATL[R] 2500 25 
250-257 AEFAEVS[K] 2700 9.0 
Bovine albumin 421-433 LGEYGFQNALIV[R] 400 1.3 
 
a [X] indicates stable isotope labeled amino acid and (C) indicates carbamidomethylated cysteine 
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Table S3. Quality control sample data. Values are light-to-heavy peptide ratios. 
 Compound Day 1 (n = 13) Day 2 (n = 14) 
 
Protein 
Amino acid 
positions 
Sequencea Mean St.dev. CV [%] Mean St.dev. CV [%] 
P
an
el
 1
 
Cystatin C 
35-50 LVGGPMDASVEEEGVR 0.29 0.011 3.8 0.31 0.013 4.2 
52-62 ALDFAVGEYNK 1.3 0.039 3.1 1.4 0.13 9.3 
β2-microglubulin 
69-78 VEHSDLSFSK 0.84 0.074 8.7 0.87 0.1 12 
102-111 VNHVTLSQPK 2.2 0.053 2.5 2.3 0.13 5.6 
Chromogranin A 
194-213 YPGPQAEGDSEGLSQGLVDR 0.3 0.051 17 0.29 0.08 27 
216-226 GLSAEPGWQAK 1.8 0.053 3 1.9 0.07 3.6 
400-412 EDSLEAGLPLQVR 1 0.031 3.1 1.1 0.058 5.4 
Secretogranin-2 
58-66 ALEYIENLR 1.4 0.047 3.4 1.6 0.18 12 
593-601 VLEYLNQEK 1.8 0.08 4.5 1.8 0.11 6.1 
Neurosecretory 
protein VGF 
64-80 NSEPQDEGELFQGVDPR 0.1 0.0035 3.4 0.11 0.0033 3 
268-278 AYQGVAAPFPK 0.71 0.028 4 0.79 0.11 14 
APP (751/770 
isoform) 
289-301 EV(C)SEQAETGP(C)R 0.078 0.012 15 0.086 0.011 13 
APP 439-450 VESLEQEAANER 0.39 0.029 7.6 0.41 0.043 10 
Albumin 
098-105 L(C)TVATLR 2.7 0.3 11 3 0.35 11 
250-257 AEFAEVSK 4.2 0.098 2.3 4.5 0.14 3.1 
Bovine albumin 421-433 LGEYGFQNALIVR 0.42 0.0055 1.3 0.56 0.044 7.9 
P
an
el
 2
 
Lysozyme C 
52-59 WESGYNTR 0.45 0.0092 2 0.51 0.017 3.3 
69-80 STDYGIFQINSR 2.3 0.066 2.9 2.8 0.34 12 
Neurexin-1 
823-841 LTVDDQQAMTGQMAGDHTR 0.24 0.0059 2.5 0.26 0.034 13 
1168-1186 VDSSSGLGDYLELHIHQGK 0.17 0.0038 2.2 0.23 0.013 5.7 
Neurexin-2 
124-133 TALAVDGEAR 0.28 0.0097 3.4 0.28 0.009 3.2 
637-651 VDLPLPPEVWTAALR 0.13 0.013 9.9 0.22 0.069 31 
Neurexin-3 
665-677 FI(C)D(C)TGTGYWGR 0.096 0.0079 8.3 0.15 0.0092 6.2 
790-807 LTVDDDVAEGTMVGDHTR 0.23 0.025 11 0.26 0.035 14 
Neuronal 
pentraxin-1 
144-152 LENLEQYSR 0.21 0.0061 3 0.24 0.0069 2.9 
386-400 LTPGEVYNLAT(C)STK 0.2 0.013 6.3 0.32 0.045 14 
Neurofascin 
67-77 GNPAPSFHWTR 0.21 0.0093 4.4 0.26 0.029 11 
702-719 VIAINEVGSSHPSLPSER 0.31 0.012 3.9 0.36 0.038 11 
Neurocan core 
protein 
257-269 ELGGEVFYVGPAR 0.4 0.0098 2.4 0.43 0.041 9.5 
1155-1170 DFQWTDNTGLQFENWR 0.16 0.0051 3.2 0.22 0.026 12 
Albumin 
098-105 L(C)TVATLR 2.7 0.32 12 3.2 0.39 12 
250-257 AEFAEVSK 4.2 0.09 2.2 4.6 0.13 2.8 
Bovine albumin 421-433 LGEYGFQNALIVR 0.42 0.0041 0.99 0.59 0.045 7.6 
 
a (C) indicates carbamidomethylated cysteine. 
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Figure S1. Acquisition schematics for (a) panel 1 and (b) panel 2. The red bars indicate the acquisition windows 
(at least 4 min) for each peptide (traces in orange). At most 4 peptides were acquired at the same time. The set 
gradients are shown in pink, while in blue is shown the actual conditions at time of spraying (the time delay due 
to the dead volume of the LC system was about 7 min). 
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Figure S2. Extracted ion chromatograms for transitions used and example MS/MS acquisitions for all peptides analysed. (a)-(p) panel 1 and (q) - (ag) panel 2. 
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(a) Cystatin C CysC_52-62
ALDFAVGEYNK
RT: 34.16 AV: 1 NL: 2.35E4
FTMS + p ESI Full ms2 616.35@hcd24.00 [200.00-1285.00]
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2-microglubulin b2M_69-78
VEHSDLSFSK
RT: 15.89 AV: 1 NL: 1.33E6
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200 300 400 500 600 700 800 900 1000 1100 1200
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
A
b
u
n
d
a
n
c
e
568.24
476.26
468.25242.16
389.23
340.13 520.25
681.32 791.40
589.35
460.73
750.34 798.34
867.36 928.46 1176.73
Time [min]
Time [min]
(c) 2-microglubulin b2M_102-111
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Chromogranin A CHGA_194-213
YPGPQAEGDSEGLSQGLVDR
RT: 28.53 AV: 1 NL: 1.98E5
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(e) Chromogranin A CHGA_216-226
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(f) Chromogranin A CHGA_400-412
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Secretogranin-2 SCG2_58-66
ALEYIENLR
RT: 34.82 AV: 1 NL: 2.52E5
FTMS + p ESI Full ms2 563.85@hcd22.00 [200.00-1175.00]
200 300 400 500 600 700 800 900 1000 1100
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
A
b
u
n
d
a
n
c
e
920.44
1019.51
595.31
213.16 510.29365.22 936.48807.44
566.80
644.37494.26314.17
703.30 902.43 1124.57
1059.57
(h) Albumin HSA_098-105
LcTVATLR
RT: 19.49 AV: 1 NL: 1.22E8
FTMS + p ESI Full ms2 470.25@hcd18.00 [200.00-985.00]
200 300 400 500 600 700 800 900
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
A
b
u
n
d
a
n
c
e
660.41
274.12
670.41
460.29
559.36
820.44467.26
321.70257.10 410.72
569.37472.27
830.45
711.42642.40 802.43527.27 840.43
(n)
26 
 
   
Neurosecretory protein VGF VGF_64-80
NSEPQDEGELFQGVDPR
RT: 34.05 AV: 1 NL: 6.53E5
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(j) Neurosecretory protein VGF VGF_268-278
AYQGVAAPFPK
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Amyloid precursor protein APP(751,770)_289-301
EVcSEQAETGPcR
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(l)
Amyloid precursor protein APP(total)_439-450
VESLEQEAANER
150421_CSF1_Other_015 #2636 RT: 17.32 AV: 1 NL: 1.36E5
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Albumin HSA_098-105
LcTVATLR
RT: 19.49 AV: 1 NL: 1.22E8
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(n) Albumin HSA_250-257
AEFAEVSK
RT: 15.13 AV: 1 NL: 2.56E8
FTMS + p ESI Full ms2 443.25@hcd18.00 [200.00-930.00]
200 300 400 500 600 700 800 900
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
A
b
u
n
d
a
n
c
e
680.36
688.38533.29
348.16 462.26234.15 809.41541.31440.73 470.27242.16 662.35396.20 576.27 734.34 827.41
(o) Bovine serum albumin BSA_421-433
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(q) Lysozyme C LysC_52-59
WESGYNTR
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(r) Lysozyme C LysC_69-80
STDYGIFQINSR
RT: 39.79 AV: 1 NL: 5.91E5
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(s) Neurexin-1 NRXN1_823-841
LTVDDQQAMTGQMAGDHTR
RT: 23.62 AV: 1 NL: 4.22E4
FTMS + p ESI Full ms2 694.50@hcd26.00 [200.00-2155.00]
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(t) Neurexin-1 NRXN1_1168-1186
VDSSSGLGDYLELHIHQGK
RT: 39.93 AV: 1 NL: 2.45E5
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(u) Neurexin-2 NRXN2_124-133
TALAVDGEAR
RT: 17.11 AV: 1 NL: 2.32E6
FTMS + p ESI Full ms2 504.75@hcd22.00 [200.00-1055.00]
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(v) Neurexin-2 NRXN2_637-651
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(w) Neurexin-3 NRXN3_665-677
FIcDcTGTGYWGR
RT: 32.78 AV: 1 NL: 6.41E4
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(x) Neurexin-3 NRXN3_790-807
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(y) Neuronal pentraxin-1 NPTX1_144-152
LENLEQYSR
RT: 22.42 AV: 1 NL: 1.15E5
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(z) Neuronal pentraxin-1 NPTX1_386-400
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(aa) Neurofascin NFASC_67-77
GNPAPSFHWTR
RT: 28.09 AV: 1 NL: 1.25E5
FTMS + p ESI Full ms2 426.05@hcd28.00 [200.00-1335.00]
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(ab) Neurofascin NFASC_702-719
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RT: 31.55 AV: 1 NL: 5.93E4
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(ac) Neurocan core protein NCANP_257-269
ELGGEVFYVGPAR
RT: 39.50 AV: 1 NL: 5.59E4
FTMS + p ESI Full ms2 700.35@hcd22.00 [200.00-1455.00]
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(ad) Neurocan core protein NCANP_257-269
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RT: 50.83 AV: 1 NL: 2.03E5
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(ae) Albumin HSA_098-105
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RT: 23.00 AV: 1 NL: 1.62E8
FTMS + p ESI Full ms2 470.25@hcd18.00 [200.00-985.00]
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(af) Albumin HSA_250-257
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RT: 16.80 AV: 1 NL: 2.78E8
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(ag) Bovine serum albumin BSA_421-433
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Figure S3. Individual peptide calibration curves for both panels. The graphs show the heavy-to-light peptide ratios (H/L) plotted vs the amount of spiked in heavy peptide (H). 
The human albumin peptides, which were included in both panels are presented as overlays. 
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Figure S4. Difference in AD vs control groups for the human serum albumin peptides included in both panel 1 (a, 
b) and panel 2 (d, e). There was no significant difference between the groups for these peptides. For both panel 
1 (c) and panel 2 (f) it can be concluded from the small variation of the bovine serum albumin control peptide 
used to monitor the tryptic digestion that the overall reproducibility was good. L/H ratio denotes light-to-heavy 
peptide ratio. 
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